Abstract Human Vc2Vd2 T cells exhibit T cell receptor-dependent, MHC-unrestricted recognition of antigen and play important roles in tumor and pathogen immunity. To characterize antigen recognition by the Vc2Vd2 TCR, we used the combined approach of spectratyping and CDR3 sequence analysis that measures changes in the TCR repertoire before and after stimulation with a phosphoantigen (isopentenyl pyrophosphate) or an irradiated tumor cell line (Daudi B lymphoma). Here we describe common Vc2 chains that are substantially involved in the response to both phosphoantigens and tumor cells. The recognition properties of common Vc2 chains explains the observation that Vc2Vd2 T cells expanded by phosphoantigen stimulation specifically recognize and kill some but not all tumor cell lines. Our studies further justify efforts to stimulate tumor immunity by administering low molecular weight phosphoantigens and boosting the frequency and tumor effector functions of circulating Vc2Vd2 T cells.
Introduction
A subset of CD3 + T cells marked by expression of the cd T cell receptor (TCR) is important for tumor surveillance [20] and for control of tolerance, inflammation and pathogen immunity [1] . Human cd T cells comprise 1-10% of circulating lymphocytes [5, 7, 13, 34] and the major subset expresses the Vc2Vd2 TCR but not the lineage determinants CD4 or CD8 [2] . The Vc2Vd2 T cell population is largely effector memory [23] and is potently cytotoxic for the Daudi B cell lymphoma [30] and other tumor targets [10, 21, 26, 39] . Because Vc2Vd2 T cells represent an abundant effector memory population that is cytotoxic for tumor cells, there is a growing interest in understanding these cells and exploiting their capabilities in the development of new immunotherapies against malignancies [27, 41] .
The lack of information about tumor antigens recognized by the Vc2Vd2 TCR impedes our understanding of cd T cell regulation. We know that Vc2Vd2 T cells respond to stimulation with low molecular weight, non-peptidic antigens including intermediates of sterol biosynthesis (such as isopentenyl pyrophosphate) [9, 16, 18, 35] , aminobisphosphonate drugs [11, 27] and alkylamines [3] . Vc2Vd2 T cells proliferate after stimulation with these agents and respond similarly to some tumor cell lines including the Daudi B cell lymphoma [4, 22, 25, 30] . Tumor recognition is independent of classical MHC molecules, there is no defined requirement for antigen processing [13] , and various tumor ligands have been implicated including HSP60 [28] and an F1 ATPase-related structure [37] . Cell lines expanded after stimulation with phosphoantigens or tumors are enriched for the Vc2-Jc1.2 rearrangement [18] and are potently cytotoxic for some tumors [10, 38] . Stimulation also induces expression of Type 1 cytokines (IFN-c, TNF-a, RANTES, MIP-1a, MIP-1b and Lymphotactin among others) [8, 14, 29, 40] and can lead to surface expression of CD107a, a marker for cytotoxic effector cells [14] . Experimental data argue against TCR binding to phosphoantigens, aminobisphosphonates or alkylamines and we do not understand why some (but not all) tumor cell lines are stimulatory or why Vc2Vd2 T cell lines are potently cytotoxic for tumor cells. Part of the problem reflects unusual features of the cd TCR repertoire.
Beginning early in life, a strong bias emerges for the Vc2Vd2 TCR in blood cd T cell populations [7] . Within the Vc2 repertoire there is selection for chains expressing the Jc1.2 segment [17] , one of five functional Jc segments. Repertoire bias is a product of chronic positive selection for Vc2-Jc1.2 that is driven by self or ubiquitous antigens. The same bias is common to most human beings irrespective of haplotype [12, 17] and is nearly identical in human and nonhuman primates [6, 18, 36] . In contrast, the highly diverse ab TCR repertoire is shaped by MHC-dependent positive and negative selection mechanisms in the thymus and does not show an obvious bias in the absence of infection or immunization [33] .
Studies on Vc2Vd2 T cells are hampered by having few of the tools that are used commonly to study ab TCR recognition. A lack of known presenting molecules coupled with the inability to define tumor antigens has prevented the use of tetramers, epitope peptides, or similar approaches to study the cd TCR. Accordingly, we looked directly at the Vc2 repertoire and its changes after treatment in vitro with model tumor cell (Daudi B cell lymphoma) or phosphoantigen (isopentenyl pyrophosphate) stimulators to understand the mechanism for antigen recognition. We define similarities and differences in the response to tumor cells or phosphoantigens by looking for Vc2 chain sequences that are expanded preferentially after exposure to either stimulus. What emerges is a map of the complex responses for an entire T cell population exposed to two different antigens. The balance of common and specific recognition describes the capacity of this unique T cell subset to be triggered by phosphoantigens and respond with tumor cytotoxicity.
Materials and methods

Collection and preparation of lymphocytes
Heparinized blood was collected from six healthy volunteers with approval from the Institutional Review Board at the University of Maryland Baltimore and informed consent of the donors. Peripheral blood mononuclear cells were isolated by centrifugation over Ficoll-Paque density gradients as described by the manufacturer (Pharmacia, Uppsala, Sweden). Approximately 5 · 10 5 cells were cultured in supplemented RPMI-1640 medium (R10) containing 10% fetal bovine serum (FBS), 2 mM L-glutamine (Gibco, Grand Island, NY), 1 U/ml penicillin/streptomycin (GIBCO, Grand Island, NY) and 100 U/ml recombinant human interleukin-2 (rhIL-2) (Tecin, Biological Resources Branch, NIH, Bethesda, MD). Isopentenyl pyrophosphate (IPP) (Sigma, St. Louis, MO) was added to a final concentration of 15 lM or irradiated (120 Gy) Daudi B cells were added at a ratio of 2:1 Daudi:PBMC. Cultures were incubated for 2 weeks at 37°C with 5% CO 2 and were replenished every 3-4 days by adding IL2-supplemented medium without IPP or Daudi.
Tumor cell lines
Daudi B cells (CCL-213, ATCC) and MOLT-4 T cells (CRL-1582, ATCC) were cultured in R10 additionally supplemented with 4.5 g/l glucose, 1.5 g/l NaHCO 3 , 10 mM HEPES and 1 mM sodium pyruvate. Several tumor cell lines were selected because of their derivation from HIV-associated malignancies, including: BC-1, BC-2, BL-5, BL-8, IBL-4 (provided kindly by William Harrington, University of Miami) and 2F7. These lines contain no HIV proviral DNA and express no detectable HIV antigens. BC-1 (CRL-2230, ATCC) and BC-2 (CRL-2231, ATCC) were cultured in RPMI-1640 supplemented with 2 mM L-glutamine, 1 U/ml penicillin/streptomycin and 20% non-heat inactivated FBS. B cell tumor lines BL-5, BL-8 and IBL-4 were kindly provided by Dr. William Harrington (University of Miami, Miami, FL) and cultured in IMDM supplemented with 2 mM L-glutamine, 1 U/ml penicillin/ streptomycin and 10% non-heat inactivated FBS. T cell line 2F7 (CRL-10237, ATCC) is cultured in R10 supplemented with 0.05 mM b-mercaptoethanol (GIBCO, Grand Island, NY).
Calcein-release cytotoxicity assay
To quantify the cytotoxic capacity of Vc2Vd2 T cells we used a non-radioactive, fluorometric cytotoxicity assay involving the dye calcein-acetoxymethyl (calcein-AM) [32] . Tumor targets were labeled for 15 min with 2 lM calcein-AM (Molecular Probes, Eugene, OR) at 37°C in 5% CO 2 and then washed once with phosphate-buffered saline (PBS). Cells were combined at various effector:target (E:T) ratios in 96 well V-bottom microtiter plates (Corning Inc., Corning, NY) and incubated at 37°C in 5% CO 2 Total RNA was extracted from at least 10 6 cells using the RNeasy Mini Kit as described by the manufacturer (Qiagen, Valencia, CA). One microgram of total RNA was then converted into cDNA using the Reverse Transcription System (Promega, Madison, WI) in a reaction containing: 500 ng of oligonucleotide A (T 15 V), 1 mM deoxynucleotriphosphates, 5 mM MgCl 2 , 10 mM Tris-HCl pH 8.8, 50 mM KCl, 0.1% Triton x-100, 18 units of avian myeloblastosis virus reverse transcriptase and 10 units of RNasin ribonuclease inhibitor. Each reaction was incubated at 42°C for 2 h, then cDNA were diluted to 100 ll by adding to the reaction 80 ll deionized water. PCR reactions were performed using 5 ll cDNA as template and 500 nM each of formard and reverse primers, 0.2 mM dNTPs, 2 mM MgCl 2 , 10 mM Tris-HCl pH 8.8, 50 mM KCl, 0.1% Triton x-100 and 1 unit of AmpliTaq Gold (Applied Biosystems, Foster City, CA). The following primers were used: oligo-Vc2 (5¢-ATCAACGCTGGC AGTCC-3¢), oligo-Cc1 (5¢-GTTGCTCTTCTTTTCTT GCC-3¢), 5¢ b-actin (5¢-GTGGGGCGCCCCAGG CACCA-3¢) and 3¢ b-actin (5¢-CTCCTTAATGTCA CGCACGATTTC-3¢). PCR was run with the following profile: denaturation for 1 min at 94°C; 5 min at 68°C; 45 cycles (45 s at 94°C, 1 min at 60°C, 1 min at 72°C); extension for 10 min at 72°C. PCR products were separated on a 2% agarose/Tris-acetate-ethylenediaminetetraacetic acid buffer (TAE) gels containing 0.5 lg/ml ethidium bromide.
Spectratype analysis
Primer extension reactions were performed as described previously [18] . Each reaction contained 1 ll PCR product, 3 mM MgCl 2 , 0.2 mM dNTP, 0.2 units Taq DNA polymerase (Promega, Madison, WI), 10 mM Tris-HCl pH 8.8, 50 mM KCl, and 0.1 lMcarboxyfluorescein (6-FAM)-labeled primer (Cc6-FAM for Vc2 chains: 5¢-AATAGTGGGCTTGGGG GAAAC-3¢; Cd16-FAM for Vd2 chains: 5¢-AC-GGATGGTTTGGTATGAGG-3¢). Four microliters of run-off products were diluted in deionized formamide and 1 ll of N,N,N¢,N¢-trimethyl-6-rhodaminelabelled molecular size standard was added to each sample. After a denaturation step (5 min at 95°C followed by immediate quenching on ice), products were loaded on an Applied Biosystem microcapillary genetic analyzer (Perkin-Elmer, Foster City, CA) and run for either 27 (Vc2 chains) or 24 (Vd2 chains) minutes on a performance-optimized polymer (POP-4). Molecular size and relative frequency of extension products were determined using Genescan software (Perkin-Elmer, Foster City, CA). To standardize the data irrespective of the run-off primer position, CDR3 length variation was expressed in terms of the total Vc2 or Vd2 coding region lengths. Run-off product lengths were corrected by adding the length of the known Vc2 or Vd2 mRNA coding regions outside the run-off product. According to this calculation, the major peak for Vc2 chains is 996 coding nucleotides and for unspliced Vd2 chains is 1,029 nucleotides with corresponding run-off product lengths of 447 and 193 nucleotides, respectively.
Cloning and sequencing PCR products were purified by gel extraction using a Qiaquick Gel Extraction kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Purified products were denatured (1 min at 94°C), incubated for 30 min at 72°C with 2 mM MgCl 2 , 0.2 mM dATP and 2.5 units Amplitaq Gold (AB, Foster City, CA), then ligated into the pCR2.1 TOPO TA cloning vector (Invitrogen, Carlsbad, CA). Ligated vector was transfected into TOP10F' competent cells using the TA Cloning kit (Invitrogen) and bacterial colonies were grown overnight on agar plates containing 50 lg/ml ampicillin, 500 lM isopropylthiogalactoside (IPTG) and 80 lg/ml bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal). Colonies containing recombinant plasmids were cultured overnight and plasmid DNA were purified using the Wizard Plus Minipreps DNA purification kit (Qiagen, Valencia, CA). Sequencing reactions were done with the Bigdye v3.1 fluorescent sequencing kit (AB, Foster City, CA) using both M13F and M13R oligonucleotide primers for each sample. Sequences were analyzed on an automated sequencer ABI3700 and aligned using Sequencher (GeneCodes Corp, Ann Arbor, MI) and MacClade software.
Vc2, Jc1.1, Jc1.2, Jc1.3/2.3, Jc2.1, and Cc1 were identified by comparison to GenBank accession numbers X07205, X08084, M12950, M12960/M12961, M16016, M14996, respectively, and TCRc locus reference sequences NG_001336 and AF159056.
Results
The adult human Vc2Vd2 repertoire is skewed toward longer Vc2 chain lengths Over several years we collected data on the Vc2 repertoire in healthy, HIV-negative adults. At present, we have data for 44 healthy adult volunteers residing in North America or Africa; the distribution of Vc2 and Vd2 chain lengths were determined by spectratype analysis. Similar to previous results, we found that in healthy adult humans the Vc2 repertoire is skewed toward longer Vc2 chain lengths (Fig. 1) , without an overall bias in the distribution of Vd2 chains (data not shown). Selection for longer Vc2 chains also coincides with the specific accumulation of Vc2-Jc1.2 chains and is estimated by calculating the frequency of Vc2 chains greater than 987 nucleotides from spectratype data. Taken together, approximately 68% of all Vc2 chains co-express the Jc1.2 segment in adults. Thus, selection for the Jc1.2 segment is a common feature of the adult Vc2 repertoire and occurs independently of ethnic or geographic background. Part of these data were reported previously [17, 18] . We expanded Vc2Vd2 T cells from PBMC using IPP or Daudi stimulation and tested each line for the ability to lyse three tumor cell targets: Daudi B lymphoma cells, (Fig. 2) . MOLT-4 was unusual in that it did not stimulate Vc2Vd2 proliferation, but was lysed by Vc2Vd2 effector cells. The majority of lymphoma cell lines tested by us and others [38] neither stimulate Vc2Vd2 proliferation nor are killed by expanded effector cells. It is important to note that some expanded Vc2Vd2 lines contained other lymphocytes including NK cells that might contribute to tumor cytolysis. However, we have observed high levels of tumor killing with lines that were highly enriched (>95%) for Vc2Vd2 T cells and effectively lysed tumor cells with effector to target ratios below one. Further, the potency of effectors (in terms of specific lysis at a given E:T ratio) was the same after IPP or Daudi stimulation despite slightly higher NK cell levels in the Daudi-expanded cultures.
IPP or Daudi selectively skew Vc2 chains toward longer chain lengths
To understand how IPP or Daudi stimulation remodeled the Vc2Vd2 repertoire, we performed spectratype analyses to assess the size distribution for Vc2 and Vd2 chains after alkylphosphate or tumor stimulation. In all donors, both IPP and Daudi stimulation and subsequent cell proliferation skewed the Vc2 repertoire toward longer chain lengths but did not alter the length distribution for Vd2 chains. This was evident when cumulative frequencies for both Vc2 and Vd2 chains from all six donors were averaged and plotted (Fig. 3) . Both IPP and Daudi skewed the Vc2 repertoire toward chain lengths greater than 987 nucleotides as evidenced by rightward shifts in the cumulative frequency plots. Comparisons of Vc2 chain lengths before and after stimulation for all six donors did not reach statistical significance. However, the starting Vc2 repertoires of donors A and E were almost exclusively Vc2 chains longer than 987 nucleotides and it was difficult to detect a shift in these highly biased samples (data not shown). When these donors were excluded from the statistical analysis, we observed a significant shift for the remaining four donors after Daudi stimulation (P < 0.05). Vc2 chain lengths were normally distributed in all samples and cumulative frequency plots for Vd2 were similar before and after stimulation with IL2, IPP or Daudi (Fig. 3) , whether or not donors A and E were excluded. In terms of chain length, the effects of antigen stimulation were most apparent in the Vc2 repertoire and we continued our study with emphasis on that chain.
IPP or Daudi selectively expand Vc2-Jc1.2 + cells
We sequenced Vc2 chains before or after IPP or Daudi stimulation for four donors, all of which had significant differences between the starting and expanded spectratypes. The occurrence of discrete Vc2 CDR3 nucleotide sequences (nucleotypes), predicted amino acid sequences (clonotypes), Jc segment usage and predicted chain lengths were determined for each The stimulation index (SI) represents the increase for Vd2 lymphocytes after IPP or Daudi compared to IL2 alone. SI is calculated as the ratio of the absolute number of Vd2 lymphocytes on day 14 to the absolute number of Vd2 lymphocytes on day 14 expanded with IL2 alone c The average Vd2 frequency or stimulation index is indicated ± standard error of the mean Fig. 3 CDR3 Length distribution in the population of Vc2 or Vd2 chains before and after stimulation with IL2 alone, 15 lM IPP and IL2 or irradiated Daudi and IL2. Whole RNA was extracted from PBMC and used to amplify Vc2 or Vd2 TCR chains using appropriate primer sets. PCR-amplified TCR chains were spectratyped using a fluorophore-conjugated primer specific for the c or d chain. Peak area and distribution were compiled with GeneScan software and data plotted as the relative (left column) or cumulative frequency (right column) of each CDR3 length for Vc2 (top row) and Vd2 (bottom row) chains. Relative frequency values are the averaged relative frequency at each nucleotide chain length for six, normal healthy donors and graphs indicate chain length distribution before (empty) or after stimulation with IL2 alone (checkered), IPP and IL2 (gray) or Daudi and IL2 (black). Cumulative frequency plots show the accumulation of the averaged relative frequencies for six, normal healthy donors and were calculated by sequentially adding averaged relative frequencies from the shortest to the longest CDR3 nucleotide length. The change in Vc2 or Vd2 chain length distribution before (empty circles, broken line) or after stimulation with IL2 alone (hash mark, solid line), IPP (solid diamonds) or Daudi (solid squares) Fig. 2 IPP-or Daudi-generated Vc2Vd2 effectors potently lyse tumor cell line targets. Vd2 effectors were generated by expanding PBMC with IPP or irradiated Daudi tumor cells. Vd2 effectors were titrated over tumor cell targets Daudi (squares), MOLT-4 (circles) or IBL-4 (triangles) at various effector to target ratios. Targets were labeled intracellularly with 2 lM calcein-AM and cytotoxicity was determined by assessing the presence of released fluorescent calcein in supernatants donor before and after stimulation. Confirming and extending our previous results [18] , we observed a positive selection for Vc2-Jc1.2 chains following stimulation with either IPP or Daudi (Fig. 4) . This result was most dramatic in donors whose starting repertoire had a lower abundance of Vc2-Jc1.2 chains. In all cases, sequence analyses confirmed the results obtained by spectratyping (data not shown).
Unlike ab T cell repertoire studies where starting frequencies of particular clonotypes are below the threshold of detection by spectratyping or DNA sequencing, the Vc2 model provides a unique opportunity to observe repertoire dynamics. We calculated the relative change for each clonotype during a proliferative expansion. The ratio of clonotype frequency before and after stimulation was multiplied by the stimulation index for that culture (Table 1 ). This produced a relative stimulation index for each clonotype that measured the strength of response for cells expressing individual Vc2 chains (Fig. 5a ). Plotting the relative stimulation index for each clonotype after IPP or Daudi treatment (Fig. 5a ) demonstrated that the population contained clonotypes that varied greatly in their response to each stimulus. As expected, most responding clonotypes and all of those responding to both IPP and Daudi, used the Vc2-Jc1.2 rearrangement (data not shown). Additionally, Vc2 clonotypes that responded to both stimuli (common recognition) were often public chains because they were present in multiple, unrelated donors (Fig. 5b) .
The Vc2 chains that responded to both IPP and Daudi comprised a significant fraction of the starting Vc2 repertoire for each of these four donors. There was a trend among all four donors that IPP or Daudi promoted the expansion of common recognition Vc2 clonotypes, many of which were also public chains.
Sequences of
We divided all Vc2-Jc1.2 clonotypes into three groups based on the calculated stimulation indices to IPP or Daudi. Groups comprised clonotypes involved in common (Fig. 6a) , Daudi-specific (Fig. 6b) or IPPspecific (Fig. 6c) recognition. Relative stimulation indices varied from 1.6 (Fig. 6b, clonotype 3-02) to  1,865 (Fig. 6a, clonotype 4-01) . Although the absolute values varied, the ratios of Daudi SI to IPP SI were generally consistent for individual clonotypes from different donors. For example, the ratio of stimulation indices to IPP versus Daudi were similar in donors A and F for the clonotype 4-01, LWETQELG (Fig. 6a) . A similar consistency was observed for clonotype 4-03 in donors A and F, even though this sequence behaved differently for donors B and C. Finally, the common recognition clonotype 4-06, LWEVRELG, reacted more to Daudi than to IPP for donors C and F. Common recognition clonotypes were encoded by three nucleotypes on average, while the majority of IPP-(6/7) or Daudi-(4/6) specific clonotypes were encoded by a single nucleotype. The overall trend was for increased nucleotype redundancy among the common recognition Vc2-Jc1.2 clonotypes.
The three designated subsets of Vc2 clonotypes were aligned separately to search for consensus sequences in their CDR3 regions. We could not define consensus Vc2 CDR3 that predicted common or specific recognition (Fig. 6 ).
The Vc2 repertoire is relatively stable for years In order to justify the development of therapies that target Vc2Vd2 T cells, it is important to know that the pool of potential tumor effector cells is stable over extended intervals. For these studies, we relied on DNA sequencing data to compare the Vc2 repertoire among individual donors at more than one time point. Initially, we compared the Vc2 repertoire in eight donors for samples collected 2 years apart (Fig. 7a) . On average, we had approximately 40 sequences for each time point. We identified Vc2 nucleotypes that were present in both samples and then calculated the proportion of the Vc2 repertoire occupied by these nucleotypes at each time point. Two donors (C and E) had conserved sequences occupying between 25 and 50% of the total repertoire and represented the lowest stability. Other donors including A and D were most stable with more than 75% of the Vc2 repertoire occupied by conserved sequences.
We performed a similar analysis for three donors where Vc2 sequence data existed for samples collected 7 years earlier (Fig. 7b) . Data for the early time point were reported previously [18] ; data for the recent time point were generated during this study. On average, we had approximately 45 sequences for each time point. Remarkably, these three donors also showed a high degree of repertoire stability over this extended interval, with greater than 50% of all detected Vc2 sequences being conserved. Overall, the Vc2 repertoire is highly stable in healthy adults. It will be important for future studies to show whether changes in this repertoire might presage an increased risk for malignancy.
Discussion
Circulating Vc2Vd2 T cells exhibit robust proliferative responses to IPP or Daudi stimulation and cells expanded in either condition are comparably cytotoxic for the same Daudi cells. Analysis of the Vc2 chain repertoire showed a substantial, though incomplete overlap between clones expanded by either stimulus and this accounted for the reported ability to expand cd T cells from PBMC with phosphoantigens and obtain a line equipped for cytolytic recognition of Daudi [38] . Individual Vc2 clonotypes that responded in both stimulatory conditions were designated ''common recognition'' chains; they constituted a substantial portion of the starting repertoire in multiple donors and were expanded preferentially in stimulated cultures.
The ability to distinguish common (responding to both stimuli) and specific (responding to one stimulus) recognition clonotypes derives from unique features of the Vc2 repertoire. In adults, the major population of Vc2 chains in circulating T cells is the product of chronic selection for cells expressing the Vc2-Jc1.2 rearrangement, likely in response to self or ubiquitous antigens [24] . Cells expressing other Vc2-Jc segment rearrangements dominate the immature thymic or cord blood cd repertoire, but comprise only a minor portion of the mature Vc2 repertoire (unpublished observations and [7] ). Selective pressures favoring the Vc2-Jc1.2 rearrangement reduce diversity to such an extent that identical clonotypes are often present among unrelated donors. The Vc2 repertoire is relatively stable over extended intervals but we also note that rare adult donors have few Vc2-Jc1.2 cells and consequently poor functional responses, despite being otherwise healthy.
The abundance of particular Vc2 clonotypes in the starting cd TCR repertoire provides a unique opportunity to determine the magnitude of change during an expansion. Such measurements are not usually possible for ab T cells, because the starting frequency for any given clone is in the range of 10 -5 -10 -6 , and it is impractical to find these rare events by a bulk cDNA sequencing effort. We were able to measure the extent of proliferation for individual Vc2 T cell clones and determine whether they respond better to one or both of the model stimuli. Many Vc2 clonotypes were expanded after IPP or Daudi stimulation. In most cases, the ratio of proliferation after IPP versus Daudi was similar among donors, even though the absolute stimulation indices varied. We interpret this to mean that the response was TCR-dependent but cell expansion required other factors in the culture, likely including monocytic and dendritic cell subsets that are known to promote Vc2Vd2 T cell proliferation [15, 31] . It is important to note that few studies have ever compared the performance of identical, naturally occurring TCR clonotypes among different individuals. The degree of consistent responses is a remarkable finding and suggests a fundamental role for Vc2Vd2 T cells.
The dominant selection for common recognition Vc2 clonotypes explains why IPP or other phosphoantigen stimulators produce potent antitumor effectors. Quite apart from suggesting that the Vc2 repertoire is an example of degenerate or non-specific recognition, these data show a high degree of specificity as evidenced by the reproducible behavior of public clonotypes in different donor PBMC.
This work highlights important differences between TCR repertoire for cd and ab T cell populations. Unlike the starting ab T cell repertoire, we found numerous examples of public Vc2 clonotypes in the starting repertoire nearly all of which expressed the Jc1.2 segment; selection produced an astonishingly similar repertoire among unrelated individuals. Similar to what has been observed for public ab T cell repertoire, public Vc2 clonotypes have minimal CDR3 diversity and are predominantly composed of germline-encoded residues [19] . Historically, the disproportionate engagement of MHC molecules with CDR1/2 of the ab TCR was proposed to explain the phenomenon of public responses with minimal CDR3 diversity in these cells [19] . Our observation that both IPP and Daudi expand public Vc2 clonotypes irrespective of haplotype argues against the MHCimprinting hypothesis for cd T cells and may reflect the inherent capacity of germline-encoded TCR to recognize conserved, non-MHC restricted antigens.
The mature Vc2Vd2 T cell repertoire encodes an effector subset that is primed for rapid proliferative and cytolytic responses to phosphoantigens, tumors and infected cells. This finding supports the efforts to stimulate antitumor responses in cancer patients by The fold-increase after IPP or Daudi stimulation was listed for each Vc2-Jc1.2 clonotype from each of the four normal, healthy donors that were sequenced. The number of nucleotypes that converge to encode the same Vc2-Jc1.2 clonotype is also indicated. The fold-increase for clonotypes not detected in the starting repertoire but present following stimulation with IPP or Daudi could not be calculated and are indicated with the abbreviation n.c treatment with phosphoantigens [27, 41] . The Vc2 repertoire evolves in response to stimulation by ubiquitous or self-molecules, possibly including normal metabolites like IPP. The common selection in most persons and the absence of MHC restriction creates a repertoire dominated by public clonotypes that recognize diverse stimuli. Vc2Vd2 T cells provide a model for understanding chronic T cell responses that defy peripheral tolerance, and are poised for responses to pathogens and tumor cells. 
